There are many different ways to fight aging -- by changing your diet, staying out of the sun or getting good sleep. A new ...

Solicitors acting for renowned Nigerian author, Chimamanda Adichie, have written to Euracare Multi-Specialist Hospital, Lagos ...

Renowned Nigerian author Chimamanda Adichie has demanded accountability from a private hospital in Lagos, accusing it of ...

Something strange is happening with malnutrition. It’s by far the fastest-growing cause of death in America, soaring sixfold ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

It looks like the first strain of flu is running its course—but beware, Influenza B infection typically comes after Influenza ...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the ...

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to Repo ...